Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital
May 9, 2019 7:58 AM EDTRoth Capital analyst Scott Henry lowered the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $4.50 (from $7.00) while maintaining a Buy rating.
... More